DIHYDRALAZINE SULFATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H10N6.H2O4S
Molecular Weight	288.284
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.NNC1=C2C=CC=CC2=C(NN)N=N1

InChI

InChIKey=BWHAMWGGORIDBK-UHFFFAOYSA-N

InChI=1S/C8H10N6.H2O4S/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;1-5(2,3)4/h1-4H,9-10H2,(H,11,13)(H,12,14);(H2,1,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6477782

Dihydralazine is a compound with antihypertensive properties and is in clinical trials, where is studied its effect on kidney function and hormones in healthy individuals.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
High blood pressure 6 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6477782	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Rare liver damage caused by an antihypertensive and anti-arrhythmic agents].	1980 Apr 1	7405322
Side-effects with long-term labetalol: an open study of 251 patients in a single centre.	1983	6844370
Action of vasodilating drugs on small and large arteries of hypertensive patients.	1983 Jul-Aug	6193361
Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis.	1996 Oct-Nov	8902272
Influence of metabolic activation on the induction of micronuclei by antihypertensive drugs in L929 cells.	2001 Feb	11305783
[Hypertensive disorders in pregnancy].	2001 Feb 15	11253286
[Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns].	2001 Sep	11709746
Drug-induced lupus as a cause of relapsing inflammatory disease after renal transplantation.	2002 Aug	12234276
[Reversible loss of vision in severe preeclampsia: case report and review of the literature].	2003 Nov-Dec	14689333
Plasma volume and blood pressure regulation in hypertensive pregnancy.	2004 Jul	15201535
Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity.	2004 Mar	14978244
Flow injection chemiluminescence determination of dihydralazine sulphate based on permanganate oxidation sensitized by rhodamine B.	2004 Nov-Dec	15508136
Flow-injection chemiluminescence determination of dihydralazine sulfate based on hexacyanoferrate(III) oxidation sensitized by eosin Y.	2004 Oct 8	18969628
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.	2005	15762770
Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy.	2005 Feb	15685521
[Hypertension in pregnancy].	2006 Mar	16722158
Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?	2007 Dec	17823234
Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.	2007 Jun	17612953
Nitric oxide-deficiency regulates hepatic heme oxygenase-1.	2008 Feb	17999922
Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery.	2008 Jan	18098350
[Eclampsia at a teaching hospital in Ivory Coast: management, outcome and prognostic factors].	2008 Jul	18591699
Chemiluminescence investigation of carbon dioxide-enhanced oxidation of dihydralazine sulfate by peroxynitrite and its application to pharmaceutical analysis.	2008 Jun 2	18482603
Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.	2009	19754423
Effects of dihydralazine on renal water and aquaporin-2 excretion in humans.	2009	18728933
Emitting species in chemiluminescence reactions with acidic potassium permanganate: a re-evaluation based on new spectroscopic evidence.	2009 Sep	19353245
Hemodynamic, morphometric and autonomic patterns in hypertensive rats - Renin-Angiotensin system modulation.	2010	20126350
[Drugs during preeclampsia. Fetal risks and pharmacology].	2010 Apr	20347563
Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system.	2010 Jan	19910243
Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review.	2010 May	20166853
Autoimmune hepatitis triggered by nitrofurantoin: a case series.	2010 Sep 23	20863377
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.	2014 Jan	24085192

Patents

Sample Use Guides

In Vivo Use Guide

The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Name

Type

Language

DIHYDRALAZINE SULFATE

Common Name

English

DIHYDRALAZINE SULPHATE

Common Name

English

DIHYDRALAZINE SULFATE [MI]

Common Name

English

DIHYDRALAZINE SULFATE [MART.]

Common Name

English

Dihydralazine sulfate [WHO-DD]

Common Name

English

1,4-DIHYDRAZINOPHTHALAZINE HYDROGEN SULFATE

Systematic Name

English

1,4-DIHYDRAZINOPHTHALAZINE HYDROGEN SULPHATE

Systematic Name

English

Code System Code Type Description

EVMPD

SUB130439